SCHEMBL2926491

SCHEMBL2926491

O=C(O)c1cccc2c1[nH]c1c3ccc(Cl)cc3oc21

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNMA1 Q12791 1/20 0.50
MCL1 Q07820 1/20 0.44
TTR P02766 3/20 0.43
PBRM1 Q86U86 2/20 0.42
AHR P35869 2/20 0.41
KDM4E B2RXH2 4/20 0.41
ALDH1A1 P00352 2/20 0.41
GPR35 Q9HC97 2/20 0.41
CYP1A2 P05177 1/20 0.41
CYP2C9 P11712 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
DYRK1A Q13627 1/20 0.40
GFER P55789 2/20 0.40
MAPT P10636 1/20 0.40
PIM1 P11309 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
LMNA P02545 1/20 0.38
GLA P06280 1/20 0.38
GAA P10253 1/20 0.38
TSHR P16473 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7500571 0.90 ALDH1A1 (0.44) KCNMA1MCL1TTRPBRM1KDM4E
SCHEMBL2924487 0.84 KDM4E (0.52) KCNMA1PBRM1KDM4EALDH1A1GPR35
SCHEMBL2929416 0.81 CA12 (0.53) KCNMA1KDM4EALDH1A1GPR35L3MBTL1
SCHEMBL2933540 0.81 KCNMA1 (0.67) KCNMA1PBRM1KDM4EALDH1A1GPR35
SCHEMBL7500797 0.79 KCNMA1 (0.43) KCNMA1MCL1TTRPBRM1KDM4E
SCHEMBL2924509 0.77 GPR35 (0.44) KCNMA1PBRM1KDM4EALDH1A1GPR35
SCHEMBL7502740 0.77 PTPRF (0.44) KCNMA1TTRPBRM1KDM4EALDH1A1
SCHEMBL7503751 0.75 CA12 (0.42) MCL1PBRM1KDM4EALDH1A1GPR35
SCHEMBL7498157 0.74 CA12 (0.41) KCNMA1MCL1PBRM1KDM4EALDH1A1
SCHEMBL5323836 0.72 PTPRF (0.50) MCL1TTRAHRKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7812177-B2 Potassium channel opener having benzofuroindole skeleton ANYGEN CO., LTD. (KR) 2010-10-12 US disclosed
EP-1861092-B1 POTASSIUM CHANNEL OPENER HAVING BENZOFUROINDOLE SKELETON ANYGEN CO LTD (KR) 2010-09-15 EP disclosed
EP-1861092-A4 POTASSIUM CHANNEL OPENER HAVING BENZOFUROINDOLE SKELETON ANYGEN CO LTD (KR) 2009-04-15 EP disclosed
US-20080194837-A1 Potassium Channel Opener Having Benzofuroindole Skeleton ANYGEN CO., LTD. (KR) 2008-08-14 US disclosed
EP-1861092-A1 POTASSIUM CHANNEL OPENER HAVING BENZOFUROINDOLE SKELETON Anygen Co., Ltd. (KR) 2007-12-05 EP disclosed
WO-2006096030-A1 POTASSIUM CHANNEL OPENER HAVING BENZOFUROINDOLE SKELETON ANYGEN CO., LTD. (KR) 2006-09-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080194837-A1 Potassium Channel Opener Having Benzofuroindole Skeleton KCNJ2, KCNN3, KCNH2 KCNMA1 41/4885MCL1 3088/4885TTR 4613/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.